REBEL EM

SEPTEMBER 13, 2023

Urticaria and pruritus = MAST CELL mediated, which is treated like a standard allergic reaction. Features Urticaria and pruritis Rapid onset (1-2 hours) IgE Dependent (Type I Hypersensitivity) Reactions An allergen cross-links two or more IgE molecules on mast cells or basophils and initiates a signal cascade leading to degranulation.

Frozen Plasma 101

Frozen Plasma Allergic Reaction FFP Plasma 101

Dr. Smith's ECG Blog

MARCH 1, 2023

Sent by anonymous, written by Pendell Meyers A man in his late 40s presented to the ED with concern for allergic reaction after accidentally eating a potential allergen, then developing an itchy full body rash and diarrhea. ST depression will not always be present in 9/12 leads — as is seen in Figure-1.

Allergic Reaction 52

Allergic Reaction E-9-1-1 Epinephrine Coronary 52

REBEL EM

JANUARY 23, 2023

Background: Diphenhydramine, a first-generation antihistamine, is the most common pharmacologic agent used to treat acute allergic reactions. Patients were randomized in a 1:1 ratio. Exclusion: Presented with acute anaphylaxis, and their acute anaphylactic symptoms had not yet been treated.

Allergic Reaction 52

Allergic Reaction ED E-9-1-1 Emergency Department 52

EMDocs

NOVEMBER 13, 2023

1 One study found that CTA head and neck was ordered for 2.5% 8 The VAN (vision, aphasia, neglect) score ( Figure 1 ), first proposed by Teleb et al. 9 A later assessment of the VAN score in Beume et al. 8 The VAN (vision, aphasia, neglect) score ( Figure 1 ), first proposed by Teleb et al.

E-9-1-1 104

E-9-1-1 ALS Emergency Department ED 104

EMDocs

JANUARY 25, 2025

Answer : Leukopenia Overview Leukopenia is defined as total WBC count < 4000/mm 3 Neutropenia is the most common subset of leukopenia and is defined on absolute neutrophil count: 1 Mild (1.01.5 10^9/L) Moderate (0.50.9 10^9/L) Severe (< 0.5 10^9/L) Generalized leukopenia (i.e. 10^9/L) Moderate (0.50.9

E-9-1-1 90

E-9-1-1 EMS Allergic Reaction ED 90

This Podcast Will Kill You

JANUARY 14, 2025

Journal of Allergy and Clinical Immunology, 141(1), pp.1-9. World Allergy Organization Journal, 1, pp.S18-S26. ” Clinical & Experimental Allergy 29 (1999): 1-11. “111 years of allergen-immunotherapy: a long and successful history of the only available disease-modifier in allergic diseases.”

Allergic Reaction 52

Allergic Reaction E-9-1-1 Epinephrine ALS 52